ABL Bio, Inc.
ABL Bio, Inc.
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors | Advanced Solid Tumor | Recruiting | Phase 1 | 2025-10-01 | NCT06126666 | |
| ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors | Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2025-09-08 | NCT07158918 | |
| This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors | Advanced Solid Tumor | Recruiting | Phase 1 | 2025-02-06 | NCT04762641 |